Government authorises use of dexamethasone for COVID-19
Doctors can now administer the an anti-inflammatory to all UK hospitalised COVID-19 patients requiring oxygen
Read More
Tag: dexamethasone
Dexamethasone cut deaths by 35% in ventilated COVID-19 patients
The steroid drug significantly reduced deaths in hospitalised patients with severe respiratory complications
Read More
NICE recommends Revlimid as multiple myeloma alternative
The new indication will benefit approximately 2,100 patients.
Read More
Venclexta safety warnings in multiple myeloma patients
US regulators have posted a safety statement warning of an increased risk of death for patients receiving AbbVie’s venetoclax with bortezomib and dexamethasone for melanoma patients.
Read More
Janssen unveils new data backing wider use of Darzalex
Janssen has unveiled data from a late-stage trial backing earlier use of its first-in-class biologic daratumumab (marketed as Darzalex) in patients with mutiple myeloma.
Read More
US approves new use for BMS’ Empliciti
US regulators have expanded the treatment scope of Bristol-Myers Squibb’s Empliciti allowing its use plus pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Read More
NICE turns down Darzalex combo for pre-treated multiple myeloma
Janssen says it is disappointed that NHS cost regulators are not backing NHS use of Darzalez (daratumumab) plus bortezomib and dexamethasone (DBd) for previously treated multiple myeloma in adults.
Read More
Trial to test cancer combo in both adults and children
UK researchers have launched an early stage trial designed to help assess whether AstraZeneca and MSD’s selumetinib could be effective in combination with dexamethasone as a treatment for leukaemia.
Read More
Final NHS nod for Allergan’s Ozurdex, AbbVie’s Humira in uveitis
Cost regulators for NHS treatments in England and Wales have deemed AbbVie’s Humira and Allergan’s Ozurdex clinically and cost effective for treating adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids.
Read More
Multiple myeloma patients to get NHS access to Amgen’s Kyprolis
The National Institute for Health and Care Excellence is backing routine NHS use of Amgen’s Kyprolis as an option for treating patients with multiple myeloma at first relapse.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
